Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904531 | 0.89 | KMT2A (0.42) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL22904394 | 0.83 | KMT2A (0.45) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL22904151 | 0.81 | MEN1 (0.47) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL1366941 | 0.80 | KMT2A (0.48) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL22904598 | 0.79 | MEN1 (0.45) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL22904432 | 0.76 | SMN1; SMN2 (0.45) | KMT2AMEN1GAASMN1; SMN2KDM4E | |
| SCHEMBL22904512 | 0.75 | SMN1; SMN2 (0.48) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL22904291 | 0.75 | MEN1 (0.45) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL30708366 | 0.75 | KMT2A (0.48) | KMT2AMEN1GAASMN1; SMN2MAPT | |
| SCHEMBL17999562 | 0.75 | KMT2A (0.50) | KMT2AMEN1GAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CDR2 | VEGFA 4327/4885KMT2A 1745/4885MEN1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.